- Assay Kits
- Reagents
- Beads
- Micro Plates
- Others
Bioprocess Technology Market was valued at USD 29,356.1 million in 2023 and is expected to grow at 12.7% CAGR from 2024 to 2030. The increase in the incidence of infectious and chronic diseases. The increased demand for decadent food from wine and beer to bread, cheese, and yogurt for their enhanced variables like texture, flavour, and shelf life is expected to drive the bioprocess technology market. Bioprocess technology is an industrial process that deals with the design and advancement of instrumentation and processes involving living cells or their components to effect the desired transformation of substrates to form more specific, efficient, and renewable by-products (biomass).
Moreover, the mass production of vaccines, painkillers, and cancer therapies after approval are all applications of bioprocessing in the pharmaceutical sector. For example, in 2022 CDER approved 37 new drugs thus increasing the demand for bioprocess technologies. Furthermore, the use of consolidated bioprocessing (CBP), separate hydrolysis and fermentation (SHF), simultaneous saccharification and fermentation (SSF), and new technological developments for generating macromolecules and aromatic compounds using renewable feedstocks for petroleum-based, textiles, pharmaceutical, and food-based industries have created several opportunities for the significant growth of the market.
However, due to the growing demand for recombinant proteins for therapeutic applications, rising demand for personalized treatment, stronger R&D pipeline strategic expansion of key players the market is increasing and is expected to further increase in the forecasted years. For instance, Merck developed a new platform called BioContinuum™ for next-generation bioprocessing by converging steps to achieve bioprocessing goals. Based on products, the bioreactors segment is dominating the market owing to its continuous operations, easy-to-adapt and clean. For instance, in March 2018, Sartorius AG introduced an amber 250 HT perfusion bioreactor system for cell culture process development that provides a computerized parallel bioreactor system specially designed for rapid cell culture perfusion process development to optimize the production of therapeutic antibodies. But, the stringent regulatory policies and higher cost of technology are hindering the growth of the market.
Study Period
2024-2030Base Year
2023CAGR
12.70%Largest Market
North AmericaFastest Growing Market
North America
Increase in the R&D in life sciences research due to rise in government support for the biotechnology and biopharmaceutical industries is expected to contribute towards the growth of the market. Moreover, rise in prevalence of chronic diseases such as cancer, increase in the newer product launches, growing need for medicines and therapeutics to treat chronic diseases, and technological advancements in bioprocess technology are expected to fuel the market over the forecast period. However, high cost of R&D, high cost of equipment, and lack of skilled professionals are the major factors may restrain the growth of the market over the forecast timeframe.
By Product Type
By Technique
By Application
By End-User
The Bioprocess Technology Market size was valued at USD 29,356.1 million in 2023 and is projected to grow at a CAGR of 12.7% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The Bioprocess Technology Market Key Players are Merck Millipore (Germany), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), General Electric Company (U.K.), Bio-Rad Laboratories, Inc.(U.S.)